January 2020

Cancer Killers

Fusion Pharmaceuticals Announces Investment from Canada Pension Plan Investment Board

Fusion, Latest News / By

Hamilton, Ontario & Boston, Massachusetts.  January 13, 2020.  Seroba’s portfolio company, Fusion Pharmaceuticals Inc., a clinical-stage precision oncology company developing next-generation radiopharmaceuticals, today announced an investment commitment of up to US$20 million from Canada Pension Plan Investment Board (CPPIB).  CPPIB joins Fusion’s existing group of top-tier investors adding to the US$105 million Series B announced …

Fusion Pharmaceuticals Announces Investment from Canada Pension Plan Investment Board Read More »

Quanta Round

Quanta Announces Collaboration with B. Braun Avitum UK Ltd

Latest News, Quanta / By

Alcester, Warwickshire, UK.  13 January 2020.  Seroba’s portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical technology company that has developed a personal haemodialysis system called SC+, today announced that it has entered into an agreement with B. Braun Avitum UK Ltd (“B. Braun”) to provide products and support services to Quanta’s …

Quanta Announces Collaboration with B. Braun Avitum UK Ltd Read More »

Pq Bypass News

CMS Approves Coverage for PQ Bypass TORUS 2 IDE Trial

Latest News, PQ Bypass / By

Milpitas, California.  6 January 2020.  Seroba’s portfolio company, PQ Bypass Inc, a medical device company bringing new advancements to the treatment of peripheral artery disease (PAD), has announced that it has received approval for coverage from the Centers for Medicare and Medicaid Services (CMS) for the Investigational Device Exemption (IDE) study titled TORUS 2.  This …

CMS Approves Coverage for PQ Bypass TORUS 2 IDE Trial Read More »

We use cookies and analytics to improve your online experience and to help us to understand where our audience is and how they reach us, as well as to understand what topics and site features are of greatest interest.  To find out more, please read our Privacy Policy. By clicking on the Accept button, you consent to our use of cookies and browsing analytics.

Scroll to Top